Armata Pharmaceuticals (NYSEAMERICAN:ARMP) Announces Earnings Results

Armata Pharmaceuticals (NYSEAMERICAN:ARMP) posted its quarterly earnings results on Wednesday. The company reported ($3.16) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.38) by ($2.78), FiscalAI reports. The business had revenue of $0.79 million for the quarter, compared to the consensus estimate of $0.74 million.

Armata Pharmaceuticals Stock Up 0.0%

Shares of ARMP stock traded up $0.00 during mid-day trading on Friday, reaching $8.20. The company’s stock had a trading volume of 73,738 shares, compared to its average volume of 55,643. The company’s 50 day simple moving average is $10.44 and its 200-day simple moving average is $8.14. Armata Pharmaceuticals has a 12-month low of $1.17 and a 12-month high of $16.34. The firm has a market capitalization of $300.97 million, a PE ratio of -1.05 and a beta of 1.31.

Wall Street Analyst Weigh In

Separately, HC Wainwright raised their target price on shares of Armata Pharmaceuticals from $9.00 to $15.00 and gave the company a “buy” rating in a research note on Monday, February 23rd. Two equities research analysts have rated the stock with a Buy rating, According to data from MarketBeat.com, Armata Pharmaceuticals has an average rating of “Buy” and a consensus price target of $15.00.

Hedge Funds Weigh In On Armata Pharmaceuticals

A number of hedge funds have recently made changes to their positions in ARMP. Geode Capital Management LLC raised its stake in shares of Armata Pharmaceuticals by 5.1% in the 4th quarter. Geode Capital Management LLC now owns 109,888 shares of the company’s stock valued at $690,000 after acquiring an additional 5,342 shares during the period. Goldman Sachs Group Inc. purchased a new position in shares of Armata Pharmaceuticals in the 4th quarter valued at $284,000. Renaissance Technologies LLC raised its stake in shares of Armata Pharmaceuticals by 65.9% in the 4th quarter. Renaissance Technologies LLC now owns 68,496 shares of the company’s stock valued at $430,000 after acquiring an additional 27,200 shares during the period. Jane Street Group LLC purchased a new position in shares of Armata Pharmaceuticals in the 4th quarter valued at $108,000. Finally, State Street Corp grew its holdings in Armata Pharmaceuticals by 26.1% during the 4th quarter. State Street Corp now owns 50,800 shares of the company’s stock valued at $319,000 after purchasing an additional 10,500 shares in the last quarter. Hedge funds and other institutional investors own 3.57% of the company’s stock.

About Armata Pharmaceuticals

Armata Pharmaceuticals, Inc is a clinical-stage biotechnology company developing targeted bacteriophage therapies to address antibiotic-resistant bacterial infections. The company’s proprietary platform harnesses naturally occurring viruses that selectively infect and destroy bacterial pathogens, offering a novel approach to combating drug-resistant strains that pose significant challenges in hospital and community settings.

Armata’s pipeline includes phage-based candidates aimed at Pseudomonas aeruginosa, a common cause of hospital-acquired pneumonia and infections in cystic fibrosis patients, as well as Staphylococcus aureus and other priority pathogens.